Cancer cachexia and immunomodulation

Area of Science:

• Oncology
• Immunology
• Metabolic Disorders

Background:

• Cachexia is a debilitating condition characterized by involuntary weight loss, often complicating malignant, infectious, and inflammatory diseases.
• Its etiology is multifactorial, involving cytokines, hormones, neuropeptides, neurotransmitters, and tumor-derived factors, leading to lipolysis and protein degradation.
• Cancer cachexia is closely linked with immune dysfunction, suggesting a bidirectional relationship where the tumor impacts immunity and cachexia is mediated by immune responses.

Purpose of the Study:

• To explore the mechanisms underlying cancer cachexia and associated immune dysfunction.
• To evaluate the potential of immunomodulatory strategies in reversing cachexia and immune deficiencies in cancer patients.
• To highlight the need for further experimental and clinical research on these interventions.

Main Methods:

• Review of existing hypotheses on cachexia etiology, including cytokine involvement and tumor products.
• Analysis of various management strategies applied to cachexia and immunodeficiency.
• Discussion of the conceptual framework linking tumor, cachexia, and immune dysfunction.

Main Results:

• Cachexia is predominantly caused by cytokines and tumor products that induce significant lipolysis and protein breakdown.
• A wide range of therapeutic strategies have been employed, from nutritional support to pharmacological agents and emerging drugs.
• The interplay between cancer, cachexia, and immune dysfunction suggests that targeting both the tumor and immune pathways is crucial.

Conclusions:

• Restoring immune efficiency by targeting tumor-related cachexia and immune pathways is a promising therapeutic approach.
• Further experimental and clinical studies are essential to validate the efficacy of immunomodulatory interventions in cancer cachexia.
• A deeper understanding of the mechanisms driving cancer cachexia is key to developing effective treatments.